Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9%

ANZDATA

Article

Posted25 May 2020
PMID32450917

AuthorsPascoe, E, Philip A. Clayton, McArthur, C, Rachael C. McConnochie, Peter F. Mount, Reidlinge, D, Robison, L, Varghese, J, Vergara, L, Weinberg, L, BEST-Fluids Investigators; Australasian Kidney Trials Network, Collins, M, Dansie, K, Fahim M, Howard, K, Johnson, D

Periodical/sTrials

Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9%

Long-term cardiac surgery outcomes in kidney transplant and dialysis patients: A national registries analysis

Pregnancy after kidney transplantation: global insights based on registry data from three continents.

Kidney replacement therapy within 12 months of childbirth in Australia

Frequency of therapy alerts during the first 30 days of automated peritoneal dialysis and its relationship to time on treatment

Study Protocol for Better Evidence for Selecting Transplant Fluids (BEST-Fluids): a pragmatic, registry-based, multi-center, double-blind, randomized controlled trial evaluating the effect of intravenous fluid therapy with Plasma-Lyte 148 versus 0.9%

Explore more

Long-term cardiac surgery outcomes in kidney transplant and dialysis patients: A national registries analysis

Pregnancy after kidney transplantation: global insights based on registry data from three continents.

Kidney replacement therapy within 12 months of childbirth in Australia

Frequency of therapy alerts during the first 30 days of automated peritoneal dialysis and its relationship to time on treatment